Navigation Links
Neurobiological Technologies Reports Third Quarter Financial Results
Date:5/12/2008

. (ET) on May 13, 2008 through midnight on May 17, 2008. Replay number: (888) 203-1112 (U.S. and Canada) / (719) 457-0820 (international). Replay access code: 3838724.

About Neurobiological Technologies, Inc.

Neurobiological Technologies is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug with multiple mechanisms of action that is specifically designed to double the time period that patients can be treated after the onset of a stroke. NTI also has the right to receive royalty payments from sales of Namenda(R) (memantine HCL), an approved drug marketed for Alzheimer's disease, and the right to receive payments from the development and marketing of XERECEPT(R) (corticorelin acetate injection), an investigational drug in Phase 3 clinical development for swelling associated with brain tumors. Additionally, NTI has rights to two compounds in early-stage development for Alzheimer's and Huntington's diseases.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the timing for completion of clinical trials, obtaining approval for Viprinex, our levels of future expenditures and capital resources and our need to raise additional capital to fund our operations, as well as other risks detailed from time to time in our Annual Report of Form 10-K, and updated periodically in our Quarterly Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation t
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Sets Date for Third Quarter Financial Results
2. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
3. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
4. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies Sets Date for Research and Development Day
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies Sets Date for Second Quarter Financial Results
10. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for the ... system received a score of 0 (range -10 to +10) for its impact on ... Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes to ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... selected an optimized Erk inhibitor molecule for development, ... of a new class of potential cancer therapies. ... prime target for therapeutic intervention in cancer. Recently ... benefits for B-Raf and Mek inhibitors. Erk inhibitors ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Colo., Nov. 10, 2010 Biodesix Inc. announced today ... equity financing, lead by existing investors. The Series C ... commercialization activities for the company,s first product VeriStrat®, a ... patients with non-small cell lung cancer (NSCLC). Existing shareholders ...
... 2010 Regenicin, Inc . (OTC Bulletin Board: WDST), ... therapies to restore the health of damaged tissues and organs, ... OTC Bulletin Board from "WDST" to "RGIN.OB" effective at the ... Regenicin CEO, Randall McCoy said the change in ticker ...
... 10, 2010 Syngenta and DuPont today announced that ... effective November 8, 2010. The transaction dissolves a joint ... Hi-Bred. It enables Syngenta and Pioneer to pursue independent ... genetics and biotechnology traits. Davor Pisk, ...
Cached Biology Technology:Biodesix Completes Series C Financing and Receives Grant 2Biodesix Completes Series C Financing and Receives Grant 3Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 2Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 3Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 4
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... MD September 20, 2007) Fifteen students mentored by ... were selected to receive the 2007ASPB Summer Undergraduate Research ... devote full-time effort to his or her research project ... also includes $500 to the mentor for lab supplies, ...
... SeniorLifes Institute for Aging Research (IFAR) have examined close ... aging to help determine which genes are responsible for ... HSL studies surveyed the entire human genome (all the ... association study (GWAS), to look for common genetic variations ...
... biologists at Tufts University has discovered a dark ... on by fireflies each summer. Using both laboratory ... of firefly courtship displays, the biologists have uncovered ... be published in the November 2007 issue of ...
Cached Biology News:ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 3Hebrew SeniorLife researchers search for aging, osteoporosis genes 2Biologists expose hidden costs of firefly flashes 2Biologists expose hidden costs of firefly flashes 3
... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... on one plate. The new ArraySlide 96 ... (7mm x 7mm) individual printing surfaces for ... analysis studies. Unlike other systems, this device ... presence of contaminating adhesives. The chamber itself ...
... chambers for sealing hybridization reactions on slides. The ... on a glass slide. Reaction solution is added ... are then sealed with plastic sealing dots. Dots ... of reaction fluid. These chambers enclose a 20 ...
Biology Products: